Halozyme Therapeutics, Inc.
HALO
$62.54
-$0.41-0.65%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.02B | 947.36M | 873.30M | 862.99M | 829.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.02B | 947.36M | 873.30M | 862.99M | 829.25M |
| Cost of Revenue | 238.47M | 249.60M | 253.86M | 263.02M | 268.72M |
| Gross Profit | 776.86M | 697.75M | 619.44M | 599.97M | 560.53M |
| SG&A Expenses | 154.34M | 149.69M | 143.72M | 146.96M | 149.18M |
| Depreciation & Amortization | 71.05M | 71.05M | 71.13M | 71.20M | 71.27M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 463.85M | 470.35M | 468.71M | 481.18M | 489.18M |
| Operating Income | 551.48M | 477.01M | 404.59M | 381.81M | 340.07M |
| Income Before Tax | 557.13M | 480.09M | 416.71M | 392.12M | 348.33M |
| Income Tax Expenses | 113.04M | 87.63M | 79.41M | 73.32M | 66.74M |
| Earnings from Continuing Operations | 444.09 | 392.47 | 337.29 | 318.80 | 281.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 444.09M | 392.47M | 337.29M | 318.80M | 281.59M |
| EBIT | 551.48M | 477.01M | 404.59M | 381.81M | 340.07M |
| EBITDA | 627.09M | 553.00M | 480.80M | 458.42M | 416.93M |
| EPS Basic | 3.50 | 3.08 | 2.62 | 2.45 | 2.14 |
| Normalized Basic EPS | 2.72 | 2.33 | 1.95 | 1.81 | 1.59 |
| EPS Diluted | 3.43 | 3.02 | 2.58 | 2.42 | 2.11 |
| Normalized Diluted EPS | 2.67 | 2.29 | 1.92 | 1.79 | 1.56 |
| Average Basic Shares Outstanding | 507.31M | 509.96M | 515.08M | 519.69M | 527.78M |
| Average Diluted Shares Outstanding | 517.22M | 519.28M | 523.23M | 527.55M | 536.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
